Hope in sight TM

Our research is bringing hope to people affected by vision loss and blindness

Donate Now

Help CERA unlock the answers to AMD

Put hope in sight and help our researchers make breakthroughs and innovations that will transform our understanding and treatment of age-related macular degeneration.

Your donation will support world-first research and clinical trials that will advance our understanding of vision loss.

Take part in research

The Centre for Eye Research Australia invites corneal specialists around the world to complete this online survey on keratoconus management.


A world-leading multidisciplinary research project, investigating age-related macular degeneration and the factors that make some people more likely to lose their vision.


In this video, learn about CERA’s research into gene therapies that could halt or even reverse vision loss in patients with conditions such as inherited retinal diseases and glaucoma.

Donate to CERA

With your support, there’s hope in sight.

Your gift will contribute to our world-leading vision research, making a real difference to people affected by vision loss and blindness.

Donate now

Take part in research

We conduct world-leading clinical trials for a range of eye conditions.

Learn more about taking part in clinical trials for conditions like age-related macular degeneration, glaucoma, diabetic retinopathy and more.

Learn more

Latest News


19 May 2021

Australia’s first clinical trials of an investigational gene therapy to treat dry age-related macular degeneration (AMD) have begun at the Centre for Eye Research Australia (CERA).


01 April 2021

Scientists have used a new gene therapy technique to repair damage to nerve cell transport systems that cause vision loss in glaucoma and memory loss in dementia.


30 April 2021

A free recording of the Centre for Eye Research Australia’s healthy ageing eyes online community forum is now available.

Eye health

29 April 2021

The national diabetes eye screening program has achieved impressive milestones in its first two years.

Eye-news emails are sent to subscribers once a month

Newsletter Subscribe
Receive Appeals